HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The offering size and terms are subject to market conditions, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. The company intends to use the net proceeds to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities, and support working capital and general corporate purposes.
This offering comes at a pivotal time for HeartBeam, which recently received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. HeartBeam's platform is designed to enable cable-free, portable devices that collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, allowing physicians to identify cardiac health trends and acute conditions outside of medical facilities.
The capital raised will be critical for scaling up production and marketing of the synthesized ECG system, which could significantly improve access to cardiac monitoring for patients. Additionally, the focus on AI capabilities suggests HeartBeam aims to leverage machine learning to enhance diagnostic accuracy and predictive analytics for heart attacks and arrhythmias. The extended-wear patch development could provide continuous monitoring solutions, addressing a key gap in current cardiac care.
For more details, the full press release is available at https://ibn.fm/pxFOz and the company's cleared indications for use are outlined at https://www.heartbeam.com/indications.
